CEO Update | 8 August 2022

UK sector news to celebrate

Summertime can be a quiet time but there has been a string of high-profile announcements within the UK sector to celebrate.

Last week, RoslinCT announced that they have signed a business combination agreement with US advanced therapy CDMO Lykan Biosciences to form a global leading innovative advanced therapies CDMO. MiroBio, a company spun out of the University of Oxford and backed by Oxford Science Enterprises which focuses on antibodies, was acquired by Gilead for $405 million. Further good news in the antibody space as Apollo Therapeutics signed an exclusive license agreement with Avalo Therapeutics granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007 (camoteskimab).

Engaging with the Labour Party

While all eyes may be on who’ll be the next Conservative leader and Prime Minister, our experience from the recent BIA Parliament Day suggests that the Labour Party is busy developing its policies ready for a general election. This includes a review launched by the Shadow Chancellor, Rachel Reeves MP, looking at the environment for start-ups in the UK. We have submitted detailed evidence on the fragile state of financing for innovative young companies, difficulties with technology transfer and the importance of R&D tax credits, among other things. We have made a set of recommendations that the next Labour Government could take forward to support start-ups and continue the growth of our sector.

I am looking forward to a busy autumn engaging with decision-makers in both parties, starting with the Labour Party conference in September.  

Biomedical Catalyst Round 2

Next week, Round 2 of the Biomedical Catalyst (BMC) for Industry-led R&D is opening up for the UK registered SMEs, this stream of the BMC supports pre-market R&D projects. Innovate UK will invest up to £25 million to develop innovative solutions to address health or healthcare challenges. BIA was instrumental in securing the launch of the BMC in 2011/12 and we have made its continuation a key campaign focus. We conducted an analysis that demonstrated the economic and scientific impacts of the scheme.

I am taking a summer holiday for the next two weeks, so the excellent BIA team will ensure you are up to date with the latest in the next fortnight, and I’ll return to CEO blog duties in the first week of September when we will know who the new Prime Minister will be.

Steve circle.png

 

 

Steve Bates OBE
CEO, BioIndustry Association


More news and updates

CEO Update - 25 March 2024

I’m delighted to be opening PULSE this morning. It is a free three-day leadership and entrepreneurship training programme for up-and-coming life sciences entrepreneurs that we’ve developed and delivered with the Francis Crick Institute. Read on for the latest on EU biotech initiatives, Biosecurity Leadership Council and boost for UK cell and gene therapy.

AI in life sciences: an evolving risk landscape

In this article, Marsh’s Life Sciences industry practice leader Jenny Yu and experts from Kennedys take a look at the topic of AI in the life sciences sector, the associated risks regulation and potential liability issues, as well as how companies can seek to ‘future-proof’ themselves in the face of rapid change.

CEO Update - 18 March 2024

A year ago, the life sciences sector faced a significant challenge with the SVB UK collapse. This event threatened to disrupt vital research and development for many companies. Today, we're taking a moment to reflect on that experience and share valuable resources to help us all build a more resilient future. 

Member spotlight: Meet OMass Therapeutics

In this blog, Ros Deegan, CEO of OMass Therapeutics, a member of the BIA Board and a member of the Prime Ministers 2024 Business Council, shares how the company is pioneering new approaches to drug discovery, targeting challenging diseases with their advanced platform.

More within